Experimental murine listeriosis is a useful model for studying cytokine regulation of cell-mediated immunity to infection with intracellular pathogens. Certain cytokines (e.g., gamma interferon [IFN--y] and tumor necrosis factor alpha [TNF-u] ) are associated with resistance to Listeria monocytogenes infections (22) . While these cytokines are involved in activation of the antilisterial host response, other cytokines may block this activation. For example, we recently reported that endogenous interleukin-4 (IL-4) antagonizes host resistance to L. monocytogenes infection (15) . By neutralizing IL-4 in vivo with a monoclonal antibody (MAb), we observed reduced replication of bacteria in the spleens and livers of L. monocytogenesinfected mice. Other cytokines that suppress cell-mediated immunity, one of which is IL-10, have been recognized. IL-10 is produced by the Th2 subset of helper T cells (11, 27) , macrophages (7) , and B cells (23) . In general, it has been shown to inhibit inflammation and cellular immunity. IL-10 inhibits production of IFN-y and IL-2 by Thl helper T cells (13, 19, 28) , production of TNF-oL by macrophages and other antigen-presenting cells (2, 7, 25, 29) , and macrophage cytotoxicity (24, 26) . In contrast with these anti-inflammatory properties, IL-10 has been reported to recruit inflammatory cells in vivo. This was best demonstrated in IL-10 transgenic mice, in which pancreatic tissue produced IL-10 and exhibited localized accumulations of lymphocytes and macrophages (31) .
We recently reported that IL-10 mRNA-expressing cells were increased in the livers of mice infected with L. monocytogenes (30) . This finding suggested to us that endogenous IL-10 might dampen the protective host response to listeriosis. In the present study, we investigated the effect of partial neutralization of endogenous IL-10 on the host response to L. monocytogenes infection and on regulation of IFN-y, granulocyte-macrophage colony-stimulating factor (GM-CSF), and TNF-ot mRNA expression. We present evidence that the treatment of mice with anti-IL-10 MAb caused reduced proliferation of L. monocytogenes in the spleen and the liver. However, we also made the unexpected observation that anti-IL-10 MAb treatment caused persistence of the infection in the liver. These findings suggest that the role of IL-10 in host defense may be more complex than previously expected.
MATERIALS AND METHODS
Experimental design. Six-to eight-week-old male BDF, (C57BL/6 x DBA/2)F1 mice were obtained from the Jackson Laboratory (Bar Harbor, Maine). The (Fig. 1A) . At 3 days after challenge, the livers of anti-IL-10 MAb-treated mice exhibited a 2 loglo reduction compared with those of controls (Fig. 1B) , and their spleens yielded 2 log1o fewer L. monocytogenes organisms than those of control mice. At 5 days after challenge, anti-IL-10 MAb-treated mice continued to have significantly fewer L. monocytogenes organisms in their spleens and livers than control mice did. After day 5, however, the relationship between the two groups of mice reversed itself. The numbers of L. monocytogenes organisms in anti-IL-10 MAbtreated mice increased, whereas the numbers of L. monocytogenes organisms in the spleens and livers of control mice decreased. The observed effects of anti-IL-10 MAb treatment were at least partially due to neutralization of endogenous IL-10, as determined by measurement of IL-10 levels in serum by ELISA at 1 day after challenge. A fourfold reduction of the IL-10 levels in the serum of anti-IL-10 MAb-treated mice compared with those of controls was observed (1.0 ± 0.9 and 4.3 ± 2.2 IU/ml, respectively). IL-10 levels in serum were not decreased by treatment with the J5/D control antibody. The effects of anti-IL-10 MAb treatment on IL-10 levels in serum were transient, being comparable with the controls by 3 days after challenge.
Treatment of mice with anti-IL-10 MAb before L. mice to be 91 ± 18 U/ml. Mice treated with anti-IL-10 MAb had significantly lower AST levels in their serum during the first 5 days after L. monocytogenes challenge than control mice (Fig. 2) . By 7 days after challenge, AST levels in the serum of control mice were decreasing, while they were increasing in that of anti-IL-10 MAb-treated mice. The late onset of liver damage in anti-IL-10 MAb-treated mice reflected the persistence of L. monocytogenes infection in these mice.
Histopathoglogical differences in the livers of anti-IL-10 MAb-treated and control mice were observed during the course of the infection. One day after challenge, the livers of both groups of mice contained small granulomatous lesions with similar infiltration of inflammatory cells in the sinuses (Fig. 3A and B) . Three days after challenge, extensive hepatic sinus infiltration by macrophages and neutrophils and large granulomatous lesions were present in the livers of control L. monocytogenes-infected mice (Fig. 3C) . In contrast, the livers of anti-IL-10 MAb-treated mice had diffuse inflammatory cell infiltration of the sinuses, which consisted mostly of macrophages, and had fewer, smaller granulomatous lesions (Fig.  3D ). There were noticeably fewer neutrophils in the livers of anti-IL-10 MAb-treated mice than in those of control mice. Similar differences in liver pathology were seen at 5 days after challenge ( Fig. 3E and F) . On day 7, the control mice had fewer granulomatous lesions and less inflammatory cell infiltration in the sinuses than at earlier time points (Fig. 3G) . In addition, numerous mitotic figures were present in the hepatocytes, indicating tissue regeneration and repair. The livers of anti-IL-10 MAb-treated L. monocytogenes-infected mice still exhibited a few small granulomatous lesions and diffuse inflammatory cell infiltration of the sinuses (Fig. 3H) . Occasional necrotic hepatocytes were observed, suggesting that liver damage was continuing.
Anti-IL-10 MAb treatment before challenge with L. monocytogenes altered expression of inflammatory cytokine mRNA. We have previously reported that mRNA expression of the inflammatory cytokines TNF-a, GM-CSF, and IFN--y in the liver is increased after challenge with L. monocytogenes (30) . In the present study, we observed increased expression of TNF-a and GM-CSF mRNA in control mice at 5 and 7 days after L. monocytogenes. Mice were euthanized at 1, 3, 5, and 7 days after challenge, and portions of their livers were fixed, sectioned, and stained with hematoxylin and eosin. One day after challenge, control (A) and anti-IL-10 MAb-treated (B) mice had similar amounts of inflammatory cell infiltration and similar numbers of pyogranulomatous lesions. At 3 days after challenge, control livers (C) had more large granulomatous lesions than those of anti-IL-10 MAb-treated mice (D), which exhibited more diffuse inflammatory cell infiltration. Similar differences in liver damage between control (E) and anti-IL-10 MAb-treated (F) mice were observed at 5 days after challenge. At 7 days after challenge, the control mice (G) had fewer large granulomatous lesions than at day 5. In addition, there were numerous hepatocytes with mitotic figures (arrows), indicating tissue repair. In contrast, the anti-IL-10 MAb-treated mice (H) continued to exhibit small granulomatous lesions with a diffuse cell infiltrate consisting predominantly of macrophages. Original magnification, x 125. monocytogenes infection (Fig. 4A and B) . In contrast, expression of TNF-ot and GM-CSF mRNA was not appreciably elevated in anti-IL-10 MAb-treated mice. Control L. monocytogenes-infected mice expressed greatly increased IFN-,y mRNA levels at 3 days after challenge, which gradually decreased thereafter. In contrast, anti-IL-10 MAb-treated mice exhibited a slower increase in expression of IFN-y mRNA that continued through 7 days after challenge (Fig. 4C) . RT-PCR analysis was performed on the samples with specific primers for TNF-cx (A), GM-CSF (B), IFN-y (C), and IL-10 (D). The PCR products were blotted onto nitrocellulose filters and hybridized with 32P-labelled oligonucleotide probes internal to the amplified sequences as described in Materials and Methods. Data are the mean _ SEM counts per minute of bound radioactivity (four mice per group). Where error bars are not visible, they were smaller than the width of the symbols. Anti-IL-10 MAb-treated mice were statistically different from control mice at the time points with asterisks. *, P < 0.05; **, P < 0.001.
other mediator that has a negative regulatory effect on IL-10 mRNA transcription.
We also measured the relative differences in expression of IL-2, IL-5, IL-6, and transforming growth factor ,B (TGF-,B) mRNA expression during L. monocytogenes infection in control and anti-IL-10 MAb-treated mice. As indicated in Table 1 , anti-IL-10 MAb treatment resulted in significantly decreased expression of IL-2 mRNA, compared with that of control mice at 1 day after challenge. Both groups of mice expressed similar levels of IL-2 mRNA at 3, 5, and 7 days after challenge. Expression of IL-5 mRNA did not change significantly during the course of L. monocytogenes infection in either treatment group. Expression of IL-6 mRNA did not change in anti-IL-10 MAb-treated mice, but it increased significantly at 5 days after challenge in control mice. Expression of TGF-,B mRNA increased in control mice at 5 days after challenge and subsequently decreased at 7 days after challenge. In contrast, TGF-1 mRNA expression remained quite low in the livers of anti-IL-10 MAb-treated mice between 1 and 5 days after challenge.
At 7 days after challenge, TGF-r mRNA expression was markedly increased in anti-IL-10 MAb-treated mice, similar to the pattern of IFN-y mRNA expression observed in these mice.
Treatment with anti-IL-10 MAb before L. monocytogenes infection leads to persistent infection. As described earlier, Days after challenge when we treated mice with anti-IL-10 MAb, we observed an early reduction in the numbers of L. monocytogenes organisms in the spleen and the liver. In these first experiments, we did not follow the fate of the infection at later time points. To determine the eventual fate of the infection in anti-IL-10 MAb-treated mice, we conducted another time course experiment at 3 to 11 days after challenge. L. monocytogenes was completely cleared from the spleens of control mice but not anti-IL-10 MAb-treated mice by 11 days after challenge (Fig.  5A) . Similarly, control mice had completely eliminated L. monocytogenes from their livers by 9 days after challenge (Fig.  5B) , whereas anti-IL-10 MAb-treated mice continued to exhibit infection in their livers at 9 and 11 days after challenge. These results suggest that early neutralization of endogenous IL-10 somehow impairs host defense mechanisms required for complete elimination of L. monocytogenes in experimentally infected mice.
Administration of anti-IL-10 MAb after challenge with L. monocytogenes caused enhanced bacterial proliferation. Since anti-IL-10 MAb treatment prior to L. monocytogenes challenge resulted in persistent infection, we hypothesized that treatment with anti-IL-10 MAb after L. monocytogenes challenge would exacerbate the infection. To test this hypothesis, we treated mice with anti-IL-10 MAb at different times before and after i.v. challenge with 4 x 104 CFU of L. monocytogenes. As illustrated in Fig. 6 , bacterial replication in the liver was enhanced in mice treated with anti-IL-10 MAb at 24 or 48 h after challenge. This is in stark contrast with the reduced bacterial proliferation observed in the livers of mice treated with anti-IL-10 MAb at 2, 24, or 48 h prior to bacterial challenge. An additional experiment was conducted to verify the importance of endogenous IL-10 later in the host response to listeriosis. Mice were challenged with L. monocytogenes and treated with anti-IL-10 MAb or control antibody at 1, 3, and 5 days after challenge. The experimental design called for the mice to be euthanized 2 days after MAb treatment. However, the mice treated with anti-IL-10 MAb at 3 and 5 days after challenge died before their scheduled euthanasia at 5 and 7 days, respectively. Control antibody-treated mice exhibited the typical course of infection with predicted numbers of L. monocytogenes organisms in their spleens and livers ( Table 2) . The increased numbers of L. monocytogenes organisms in the livers of mice treated with anti-IL-10 MAb after bacterial challenge is consistent with our histopathological evidence that anti-IL-10 MAb treatment impaired the recruitment of inflammatory cells required to eliminate L. monocytogenes during the late stage of the infection.
DISCUSSION
We recently observed that IL-10 mRNA-expressing cells increased in number within the livers of mice during L. monocytogenes infection (30) . This finding compelled us to consider that IL-10 may play a significant role in the host response during listeriosis. On the basis of considerable evidence that IL-10 inhibits functions related to inflammation and cellular immunity, we predicted that endogenous IL-10 would have a negative effect on antilisterial resistance. In the present study, we treated mice with a neutralizing anti-IL-10 MAb (SXC-1) to investigate the effects of endogenous IL-10 on the host response to L. nionocytogenes infection. At the time this study was begun, SXC-1 was the only anti-mouse IL-10 MAb described as neutralizing IL-10 in vivo (17, 18) . Our results obtained with an IL-10 ELISA suggested that SXC-1 MAb treatment reduced IL-10 levels in serum by nearly 75%. It is unclear whether ELISA levels in serum indicate the availability of biologically active IL-10. It is possible that the ELISA overestimated biologically active IL-10 levels by identifying IL-10 complexed with anti-IL-10 MAb. The best indication of neutralization of IL-10 in the present study was the expected decrease in bacterial numbers in the spleens and livers of anti-IL-10 MAb-treated mice during the early stage of L. monocytogenes infection. This observation is consistent with the predicted deleterious effect of Th2 cytokines on cellular immunity (13) . In addition, the increased class II major histocompatibility complex (MHC) antigen expression by anti-IL-10 MAb-treated mice was consistent with prior evidence that IL-10 suppresses class II MHC antigen expression in vitro (8) .
Our initial observation in the present study was that anti-IL-10 MAb treatment before challenge with L. monocytogenes decreased the numbers of L. monocytogenes organisms recovered from spleens and livers during the first 5 days of infection. Similar observations have been made recently with Mycobacterium avium-infected mice (1, 6) . In these two studies, anti-IL-10 antibody treatment at the time of infection reduced the burden of M. avium in the spleens and livers of mice by 2 log10
CFU. These authors suggested that induction of IL-10 may be part of the pathogen's strategy to suppress the host resistance to M. avium, resulting in prolonged infection (1) . Both studies with M. avium, and our present study with L. monocytogenes, support the hypothesis that endogenous IL-10 can suppress the host response to infection by intracellular pathogens.
One possible way that IL-10 can suppress the host response is by inhibiting the production of IFN-y, which is important for macrophage activation. There is considerable evidence that IL-10 can suppress Thl-cell production of IFN-y both directly (1 1) and by suppression of T-cell activation by antigen-presenting cells (10, 13, 20) . However, the results of the present study are not entirely consistent with this function of IL-10. IFN-y mRNA expression at day 1 was actually higher in the livers of control mice, which had unperturbed levels of IL-10, than in those of anti-IL-10 MAb-treated mice. This argues against a substantial suppression of IFN-y expression by IL-10. The pattern of IFN--y expression followed the increase in bacterial burden, suggesting that this produced a stimulus that was stronger than IL-10-mediated suppression.
Most experimental evidence suggests that the suppressive effects of IL-10 on the host response are predominantly mediated by its effects on macrophages. For example, macrophage activation is directly inhibited by lL-10 (2). IL-10 alone, or in synergy with IL-4 and TGF-,B, inhibits the cytotoxic activity of macrophages against schistosomula of Schistosoma mansoni (24) . In a recent study with L. monocytogenes-infected mice, bacterial proliferation in the liver was suppressed when mice received exogenous IFN-y that increased MHC class II antigen expression on antigen-presenting cells that were induced with exogenous IFN-y (19) . IL-10 has been shown to suppress the expression of MHC class II antigens on human monocytes, making them less capable of activation and functioning as antigen-presenting cells (8) . In the present study, we noticed that anti-IL-10 MAb-treated mice had significantly increased MHC class II antigen expression (37.3 ± 1.5% I-Ad" macrophages in the spleens of anti-IL-10 MAb-treated mice versus 29.5 + 2.3% I-A"'+ macrophages in the spleens of control antibody-treated mice) on the third day of L. monocytogenes infection. Thus, our results suggest that endogenous IL-10, when present in the tissues during the early stages of L. monocytogenes infection, modulates some aspects of macrophage activation.
Another effect of IL-10 is inhibition of macrophage cytokine production (25) . IFN--y-activated human monocytes produce IL-1, IL-6, IL-8, TNF-ox, GM-CSF, and granulocyte colonystimulating factor; production of these cytokines was inhibited at the level of transcription by the addition of IL-10 (7). IL-10 has been reported to inhibit TNF-ot production by murine and human macrophages (2, 12, 25) . In the present study, we observed differential effects on the transcription of TNF-ct and GM-CSF in anti-IL-10 MAb-treated L. monocytogenes-infected mice compared with that in infected control mice. L. monocytogenes-infected control mice exhibited increased expression of TNF-ox and GM-CSF at 3 days after challenge, which decreased thereafter. In contrast, TNF-ot and GM-CSF mRNA expression were never increased in anti-IL-10 MAbtreated mice. Expression of TNF-ot in L. monocytogenesinfected mice has been reported to be essential for host resistance (16, 22) . In the present study, the coincidental inability to eliminate the infection and failure to induce TNF-cx mRNA expression exhibited by anti-IL-10 MAb-treated mice is intriguing. It suggests that endogenous IL-10 activity assisted the induction of TNF-ot expression in L. monocytogenesinfected mice and that this induction was important to prevent persistent infection. The scope of this study was not broad enough to determine the mechanism by which this occurred. Perhaps the most significant observation made in this study was the persistence of L. monocytogenes in anti-IL-10 MAbtreated mice. We recovered approximately 3 log,,, L. monocyto8.c.ies organisms from the spleens and livers of anti-IL-10
MAb-treated mice at 11 days after challenge, whereas control mice had completely cleared the infection by this time. This inhibition of bacterial clearance may be the result of reduced recruitment of inflammatory cells into granulomatous lesions in the livers of anti-IL-10 MAb-treated mice. This suggests that IL-10 might be involved in the recruitment of the inflammatory cells that form granulomatous lesions in the liver and are an important aspect of the host response in murine listeriosis (14) . This hypothesis is consistent with a recent report of neutrophil and macrophage recruitment into a tissue where IL-10 was being produced. In a recent study, Wogensen et al. (31) observed that transgenic mice, which expressed IL-10 in the (4, 5) , or release mediators that prevent intracellular multiplication of L. monocytogenes. This hypothesis is consistent with our observation that anti-IL-10 MAb treatment, given 1 or 2 days after challenge, was associated with increased L. monocytogenes proliferation in the liver.
In summary, this study provides evidence that endogenous IL-10 has both beneficial and detrimental roles in the host response to L. monocytogenes infection. The beneficial function appears to be associated with recruitment of inflammatory cells to foci of infection in the liver. The detrimental role is that endogenous IL-10 appears to suppress resistance during the early stage of infection. IL-10 is a promising anti-inflammatory agent that may be useful therapeutically to suppress transplant rejection and chronic inflammation during autoimmune diseases (9) . The potential uses of IL-10 as an anti-inflammatory agent must take into consideration the knowledge that IL-10 may have unexpected biological effects beyond those predicted by its role as an inhibitor of cytokine production by Thl cells, NK cells, and macrophages.
